Clinical research

Efficiency and safety of the sirolimus eluting stent in complex coronary artery lesions after cessation of dual antiplatelet therapy: fifteen months clinical outcome of the randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial

EuroIntervention 2007;3:309-314 - DOI10.4244/EIJV3I3A57.

Steffen Helqvist
Steffen Helqvist1, MD; Henning Kelbæk1*, MD; Leif Thuesen2, MD; Lene Kløvgaard1, RN; Lars R. Krusell2, MD; Erik Jørgensen1, MD; Hans E. Bøtker2, MD; Gunnar V. H. Jensen3, MD; Jens F. Lassen2, MD; Per Thayssen4, MD; Anders Galløe5, MD; Kari Saunamäki1, MD; for the SCANDSTENT Investigators
1. Rigshospitalet, Copenhagen, Denmark; 2. Skejby Sygehus, Skejby, Denmark; 3. Roskilde Amtssygehus, Roskilde, Denmark; 4. Odense Universitetshospital, Odense, Denmark; 5. Gentofte Amtssygehus, Gentofte, Denmark

Background: The randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial reported considerably less angiographic restenosis after implantation of sirolimus-e

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

percutaneous coronary interventioncomplex coronary lesionsdrug eluting stentsbare metal stentsrestenosis
Read next article
One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Latest news